KVA-12123 is under clinical development by Kineta and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KVA-12123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KVA-12123 is under development for the treatment of solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), renal cell carcinoma and head and neck cancer squamous cell carcinoma. It acts by targeting v-region immunoglobulin-containing suppressor of T cell activation (VISTA). It is administered through intravenous route as infusion. It was also under development for acute myelocytic leukemia (AML).
Kineta formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of treatments for neurodegenerative diseases. The company uses its drug discovery platform for the development of its pipeline products. Kineta‘s pipeline product candidates include YTX-7739 for the treatment of Parkinson’s disease; YTX-9184 for the treatment of dementia with lewy bodies. Other pipeline also comprises of additional programs with undisclosed product candidates that are focused on frontotemporal lobar dementia (FTLD), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Kineta is headquartered in Boston, Massachusetts, the US.
For a complete picture of KVA-12123’s drug-specific PTSR and LoA scores, buy the report here.